Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1970 Aug 1;132(2):329–352. doi: 10.1084/jem.132.2.329

HUMAN PLASMA ALPHA 2-MACROGLOBULIN

AN INHIBITOR OF PLASMA KALLIKREIN

Peter C Harpel 1
PMCID: PMC2138741  PMID: 4101346

Abstract

Activation of plasma kallikrein arginine esterase activity by kaolin resulted in peak activity at 1 min of incubation and a 50% reduction in activity at 5 min in normal plasma, and 30% reduction in the plasma of patients with hereditary angioneurotic edema who lacked the C1 inactivator. The peak esterolytic activity was inhibited by soybean trypsin inhibitor whereas the 5 min activity was resistant to this inhibitor. Acid treatment of normal and hereditary angioneurotic edema plasma destroyed the factor responsible for the fall in esterase activity at 5 min and the factor which rendered the esterase resistant to soybean trypsin inhibitor. Purified α2-macroglobulin inhibited approximately 50% of the TAMe esterase activity of purified plasma kallikrein without changing its activity toward basic amino acid esters. The interaction between the α2-macroglobulin and kallikrein resulted in alterations in the gel filtration chromatographic pattern of the TAMe esterase and biologic activity of kallikrein, indicating that kallikrein was bound to the α2-macroglobulin. The TAMe esterase activity of this complex, isolated by column chromatography, was resistant to C1 inactivator and SBTI. Studies of incubation mixtures of kallikrein, α2-macroglobulin and C1 inactivator suggested that these inhibitors compete for the enzyme, and that the α2-macroglobulin partially protects the esterase activity of kallikrein from C1 inactivator. The α2-macroglobulin isolated from kaolin-activated plasma possessed 240 times the esterolytic activity of the α2-macroglobulin purified from plasma treated with inhibitors of kallikrein and of its activation. The α2-macroglobulin blocked the uterine-containing activity and vascular permeability-inducing effects of plasma kallikrein. These studies suggest that the α2-macroglobulin is a major plasma inhibitor of kallikrein and provide a new example of an interrelationship between the coagulation, fibrinolytic, and kallikrein enzyme systems.

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALKJAERSIG N., FLETCHER A. P., SHERRY S. The mechanism of clot dissolution by plasmin. J Clin Invest. 1959 Jul;38(7):1086–1095. doi: 10.1172/JCI103885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. ALKJAERSIG N., FLETCHER A. P., SHERRY S. xi-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem. 1959 Apr;234(4):832–837. [PubMed] [Google Scholar]
  3. AUSTEN K. F., SHEFFER A. L. DETECTION OF HEREDITARY ANGIONEUROTIC EDEMA BY DEMONSTRATION OF A REDUCTION IN THE SECOND COMPONENT OF HUMAN COMPLEMENT. N Engl J Med. 1965 Apr 1;272:649–656. doi: 10.1056/NEJM196504012721301. [DOI] [PubMed] [Google Scholar]
  4. BACHMANN F., DUCKERT F., KOLLER F. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh. 1958 May 1;2(1-2):24–38. [PubMed] [Google Scholar]
  5. BECKER E. L., KAGEN L. THE PERMEABILITY GLOBULINS OF HUMAN SERUM AND THE BIOCHEMICAL MECHANISM OF HEREDITARY ANGIONEUROTIC EDEMA. Ann N Y Acad Sci. 1964 Aug 27;116:866–873. doi: 10.1111/j.1749-6632.1964.tb52552.x. [DOI] [PubMed] [Google Scholar]
  6. Becker E. L. F. The relation of complement to other systems. Proc R Soc Lond B Biol Sci. 1969 Jul 1;173(1032):383–392. doi: 10.1098/rspb.1969.0065. [DOI] [PubMed] [Google Scholar]
  7. Colman R. W. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun. 1969 Apr 29;35(2):273–279. doi: 10.1016/0006-291x(69)90278-2. [DOI] [PubMed] [Google Scholar]
  8. Colman R. W., Mason J. W., Sherry S. The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states. Ann Intern Med. 1969 Oct;71(4):763–773. doi: 10.7326/0003-4819-71-4-763. [DOI] [PubMed] [Google Scholar]
  9. Colman R. W., Mattler L., Sherry S. Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest. 1969 Jan;48(1):11–22. doi: 10.1172/JCI105959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Colman R. W., Mattler L., Sherry S. Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein. J Clin Invest. 1969 Jan;48(1):23–32. doi: 10.1172/JCI105971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DONALDSON V. H., EVANS R. R. A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. Am J Med. 1963 Jul;35:37–44. doi: 10.1016/0002-9343(63)90162-1. [DOI] [PubMed] [Google Scholar]
  12. DONALDSON V. H., ROSEN F. S. ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE. J Clin Invest. 1964 Nov;43:2204–2213. doi: 10.1172/JCI105094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Donaldson V. H. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med. 1968 Mar 1;127(3):411–429. doi: 10.1084/jem.127.3.411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. ELDER J. M., WILHELM D. L. Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. V. Activable permeability factor in human serum. Br J Exp Pathol. 1958 Aug;39(4):335–342. [PMC free article] [PubMed] [Google Scholar]
  15. Eisen V. Kinin formation and fibrinolysis in human plasma. J Physiol. 1963 May;166(3):514–529. doi: 10.1113/jphysiol.1963.sp007120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Eisen V. Observations on intrinsic kinin-forming factors in human plasma: the effect of acid, acetone, chloroform, heat and euglobulin separation on kinin formation. J Physiol. 1963 May;166(3):496–513. doi: 10.1113/jphysiol.1963.sp007119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. FASCIOLO J. C. BRADYKININOGEN, ANGIOTENSINOGEN AND KALLIDINOGEN. Br J Pharmacol Chemother. 1963 Oct;21:250–258. doi: 10.1111/j.1476-5381.1963.tb01524.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ganrot P. O. Inhibition of plasmin activity by alpha-2-macroglobulin. Clin Chim Acta. 1967 May;16(2):328–329. doi: 10.1016/0009-8981(67)90201-x. [DOI] [PubMed] [Google Scholar]
  19. Ganrot P. O. Separation of two trypsin-binding alpha-2-globulins of human serum. Clin Chim Acta. 1966 May;13(5):597–601. doi: 10.1016/0009-8981(66)90163-x. [DOI] [PubMed] [Google Scholar]
  20. HAINES A. L., LEPOW I. H. STUDIES ON HUMAN C'1-ESTERASE. I. PURIFICATION AND ENZYMATIC PROPERTIES. J Immunol. 1964 Mar;92:456–467. [PubMed] [Google Scholar]
  21. HAVERBACK B. J., DYCE B., BUNDY H. F., WIRTSCHAFTER S. K., EDMONDSON H. A. Protein binding of pancreatic proteolytic enzymes. J Clin Invest. 1962 May;41:972–980. doi: 10.1172/JCI104576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Harpel P. C. A sensitive colorimetric method for the measurement of serum C1 inactivator using the substrate N-alpha-acetyl-L-lysine methyl ester. J Immunol. 1970 Apr;104(4):1024–1030. [PubMed] [Google Scholar]
  23. Harpel P. C. C1 inactivator inhibition by plasmin. J Clin Invest. 1970 Mar;49(3):568–575. doi: 10.1172/JCI106267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Harpel P. The differentiation of esterase and fibrinolytic activity in human plasma euglobulin preparations. Thromb Diath Haemorrh. 1968 Jul 31;19(3):596–598. [PubMed] [Google Scholar]
  25. IATRIDIS S. G., FERGUSON J. H. Actie Hageman factor: a plasma lysokinase of the human fibrinolytic system. J Clin Invest. 1962 Jun;41:1277–1287. doi: 10.1172/JCI104590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Iverius P. H., Laurent T. C. Precipitation of some plasma proteins by the addition of dextran or polyethylene glycol. Biochim Biophys Acta. 1967 Feb 21;133(2):371–373. doi: 10.1016/0005-2795(67)90079-7. [DOI] [PubMed] [Google Scholar]
  27. James K., Taylor F. B., Jr, Fudenberg H. H. The effect of alpha-2-macroglobulin in human serum on trypsin, plasmin, and thrombin activities. Biochim Biophys Acta. 1967 Feb 21;133(2):374–376. doi: 10.1016/0005-2795(67)90080-3. [DOI] [PubMed] [Google Scholar]
  28. KAGEN L. J., LEDDY J. P., BECKER E. L. THE PRESENCE OF TWO PERMEABILITY GLOBULINS IN HUMAN SERUM. J Clin Invest. 1963 Aug;42:1353–1361. doi: 10.1172/JCI104819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. KAGEN L. J. SOME BIOCHEMICAL AND PHYSICAL PROPERTIES OF THE HUMAN PERMEABILITY GLOBULINS. Br J Exp Pathol. 1964 Dec;45:604–611. [PMC free article] [PubMed] [Google Scholar]
  30. KINGDON H. S., DAVIE E. W., RATNOFF O. D. THE REACTION BETWEEN ACTIVATED PLASMA THROMBOPLASTIN ANTECEDENT AND DIISOPROPYLPHOSPHOFLUORIDATE. Biochemistry. 1964 Feb;3:166–173. doi: 10.1021/bi00890a005. [DOI] [PubMed] [Google Scholar]
  31. KOCH W. Relationship between air temperature and mean radiant temperature in thermal comfort. Nature. 1962 Nov 10;196:587–587. doi: 10.1038/196587a0. [DOI] [PubMed] [Google Scholar]
  32. Kellermeyer R. W., Graham R. C., Jr Kinins--possible physiologic and pathologic roles in man. N Engl J Med. 1968 Oct 17;279(16):859–concl. doi: 10.1056/NEJM196810172791605. [DOI] [PubMed] [Google Scholar]
  33. Kunitz M. CRYSTALLINE SOYBEAN TRYPSIN INHIBITOR : II. GENERAL PROPERTIES. J Gen Physiol. 1947 Mar 20;30(4):291–310. doi: 10.1085/jgp.30.4.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. LANDERMAN N. S., WEBSTER M. E., BECKER E. L., RATCLIFFE H. E. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy. 1962 Jul-Aug;33:330–341. doi: 10.1016/0021-8707(62)90032-1. [DOI] [PubMed] [Google Scholar]
  35. LEVY L. R., LEPOW I. H. Assay and properties of serum inhibitor of C'l-esterase. Proc Soc Exp Biol Med. 1959 Aug-Sep;101:608–611. doi: 10.3181/00379727-101-25034. [DOI] [PubMed] [Google Scholar]
  36. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  37. Lanchantin G. F., Plesset M. L., Friedmann J. A., Hart D. W. Dissociation of esterolytic and clotting activities of thrombin by trypsin-binding macroglobulin. Proc Soc Exp Biol Med. 1966 Feb;121(2):444–449. doi: 10.3181/00379727-121-30800. [DOI] [PubMed] [Google Scholar]
  38. Laurell A. B., Lundh B., Malmquist J. Inability of a highly purified streptokinase preparation to inactivate complement in serum. Acta Pathol Microbiol Scand. 1965;64(3):318–328. doi: 10.1111/apm.1965.64.3.318. [DOI] [PubMed] [Google Scholar]
  39. MARGOLIS J. The mode of action of Hageman factor in the release of plasma kinin. J Physiol. 1960 May;151:238–252. doi: 10.1113/jphysiol.1960.sp006434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. MEHL J. W., O'CONNELL W., DEGROOT J. MACROGLOBULIN FROM HUMAN PLASMA WHICH FORMS AN ENZYMATICALLY ACTIVE COMPOUND WITH TRYPSIN. Science. 1964 Aug 21;145(3634):821–822. doi: 10.1126/science.145.3634.821. [DOI] [PubMed] [Google Scholar]
  41. MILES A. A., WILHELM D. L. Enzyme-like globulins from serum reproducing the vascular phenomena of inflammation. I. An activable permeability factor and its inhibitor in guinea-pig serum. Br J Exp Pathol. 1955 Feb;36(1):71–81. [PMC free article] [PubMed] [Google Scholar]
  42. Miles A. D. The kinin system. A history and review of the kinin system. Proc R Soc Lond B Biol Sci. 1969 Jul 1;173(1032):341–349. doi: 10.1098/rspb.1969.0060. [DOI] [PubMed] [Google Scholar]
  43. NIEWIAROWSKI S., PROU-WARTELLE O. [Role of the contact factor (Hageman factor) in fibrinolysis]. Thromb Diath Haemorrh. 1959 Sep 1;3:593–603. [PubMed] [Google Scholar]
  44. Nagasawa S., Takahashi H., Koida M., Suzuki T., Schoenmakers J. G. Partial purification of bovine plasma kallikreinogen, its activation by the Hageman factor. Biochem Biophys Res Commun. 1968 Aug 21;32(4):644–649. doi: 10.1016/0006-291x(68)90287-8. [DOI] [PubMed] [Google Scholar]
  45. Nomenclature of complement. Bull World Health Organ. 1968;39(6):935–938. [PMC free article] [PubMed] [Google Scholar]
  46. OWREN P. A., AAS K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3(3):201–208. doi: 10.3109/00365515109060600. [DOI] [PubMed] [Google Scholar]
  47. PENSKY J., LEVY L. R., LEPOW I. H. Partial purification of a serum inhibitor of C'1-esterase. J Biol Chem. 1961 Jun;236:1674–1679. [PubMed] [Google Scholar]
  48. POLSON A., POTGIETER G. M., LARGIER J. F., MEARS G. E., JOUBERT F. J. THE FRACTIONATION OF PROTEIN MIXTURES BY LINEAR POLYMERS OF HIGH MOLECULAR WEIGHT. Biochim Biophys Acta. 1964 Mar 16;82:463–475. doi: 10.1016/0304-4165(64)90438-6. [DOI] [PubMed] [Google Scholar]
  49. PROCTOR R. R., RAPAPORT S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961 Sep;36:212–219. doi: 10.1093/ajcp/36.3.212. [DOI] [PubMed] [Google Scholar]
  50. Pensky J., Schwick H. G. Human serum inhibitor of C'1 esterase: identity with alpha-2-neuraminoglycoprotein. Science. 1969 Feb 14;163(3868):698–699. doi: 10.1126/science.163.3868.698. [DOI] [PubMed] [Google Scholar]
  51. RAPAPORT S. I., SCHIFFMAN S., PATCH M. J., WARE A. G. A simple, specific one-stage assay for plasma thromboplastin antecedent activity. J Lab Clin Med. 1961 May;57:771–780. [PubMed] [Google Scholar]
  52. RATNOFF O. D., DAVIE E. W. The purification of activated Hageman factor (activated factor XII). Biochemistry. 1962 Nov;1:967–975. doi: 10.1021/bi00912a005. [DOI] [PubMed] [Google Scholar]
  53. RATNOFF O. D., LEPOW I. H. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med. 1957 Aug 1;106(2):327–343. doi: 10.1084/jem.106.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. RATNOFF O. D., MILES A. A. THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR. Br J Exp Pathol. 1964 Jun;45:328–345. [PMC free article] [PubMed] [Google Scholar]
  55. Ratnoff O. D., Naff G. B. The conversion of C'IS to C'1 esterase by plasmin and trypsin. J Exp Med. 1967 Feb 1;125(2):337–358. doi: 10.1084/jem.125.2.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Ratnoff O. D., Pensky J., Ogston D., Naff G. B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J Exp Med. 1969 Feb 1;129(2):315–331. doi: 10.1084/jem.129.2.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. SCHEIDEGGER J. J. Une micro-méthode de l'immuno-electrophorèse. Int Arch Allergy Appl Immunol. 1955;7(2):103–110. [PubMed] [Google Scholar]
  58. SCHIFFMAN S., RAPAPORT S. I., WARE A. G., MEHL J. W. Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma. Proc Soc Exp Biol Med. 1960 Dec;105:453–455. doi: 10.3181/00379727-105-26138. [DOI] [PubMed] [Google Scholar]
  59. SIEGELMAN A. M., CARLSON A. S., ROBERTSON T. Investigation of serum trypsin and related substances. I. The quantitative demonstration of trypsinlike activity in human blood serum by a micromethod. Arch Biochem Biophys. 1962 Apr;97:159–163. doi: 10.1016/0003-9861(62)90058-9. [DOI] [PubMed] [Google Scholar]
  60. Sherry S., Alkjaersig N. K., Fletcher A. P. Observations on the spontaneous arginine and lysine esterase activity of human plasma, and their relation to Hageman factor. Thromb Diath Haemorrh Suppl. 1966;20:243–247. [PubMed] [Google Scholar]
  61. WEBSTER M. E., PIERCE J. V. Action of the kallikreins on synthetic ester substrates. Proc Soc Exp Biol Med. 1961 May;107:186–191. doi: 10.3181/00379727-107-26575. [DOI] [PubMed] [Google Scholar]
  62. Webster M. E. Human plasma kallikrein, its activation and pathological role. Fed Proc. 1968 Jan-Feb;27(1):84–89. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES